The U.K.’s National Institute for Health and Care Excellence recommended the use of Firmagon (degarelix) for men with advanced hormone-dependent prostate cancer with spinal metastases. This announcement follows a three-year review process and NICE’s most recent draft Appraisal Consultation Document published in June 2015, which recommended against the use of Firmagon within its marketing authorization...
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
